Pallas Capital Advisors LLC Erasca, Inc. Transaction History
Pallas Capital Advisors LLC
- $2.24 Billion
- Q1 2025
A detailed history of Pallas Capital Advisors LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 11,510 shares of ERAS stock, worth $15,078. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,510Holding current value
$15,078% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$29.6 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$22.7 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$21.2 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$17 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$16.7 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $160M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...